Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 3INDUSTRY 2FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 5Other hematologic neoplasm 5Thoracic 4Lymphoid 3Gastrointestinal 3Tumor-Agnostic 2Sarcoma 2Plasma cell 2Head & Neck 2Genitourinary 2Dermatologic 2Breast 2Gynecologic 1CNS 1

Conditions

Urinary Bladder Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Carcinoma, Renal Cell 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 164Prednisone 130enzalutamide 127Docetaxel 122Abiraterone Acetate 95Nivolumab 93Gemcitabine 71Sunitinib 67atezolizumab 50abiraterone 50Leuprolide 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 48Cisplatin 48radium Ra 223 dichloride 39Sorafenib 39darolutamide 38apalutamide 38Ipilimumab 38Carboplatin 37Prednisolone 33Everolimus 33Axitinib 32cabozantinib 31avelumab 31pazopanib 30Bevacizumab 30Paclitaxel 29enfortumab vedotin 28bicalutamide 28Cyclophosphamide 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Tablets × Genitourinary × Clear all
NCT01976741 2021-05-06

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Bayer

Phase 1 Completed
168 enrolled 59 charts
GenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

NCT01865747 2021-04-27

METEOR

Exelixis

Phase 3 Completed
658 enrolled 15 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡